Comprehensive Genomic Profiling for Pan-Cancer
Precision oncology decision support (PODS) for personalized cancer therapy
Surveillance for Cancer Recurrence and Assessment of Treatment Efficacy
Advancing Precision Cancer Treatment: Expanding Opportunities
Precision medicine employs personalized treatment strategies informed by comprehensive genetic testing and the specific cancer type. This approach aims to assess the patient's potential response to therapies.
By strategically combining targeted therapy, immunotherapy, and traditional chemotherapy within a treatment plan tailored to the molecular profile of the patient's tumor, precision medicine endeavors to enhance survival outcomes for cancer patients.
Transforming Cancer Care: Breakthroughs in Personalized Treatment and Cancer Tracking
The K-4CARE test is a comprehensive genomic profiling assay designed to generate a detailed molecular profile of solid tumors. The scope of testing is recommended by the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and U.S. Food and Drug Administration (FDA).
By analyzing a broad range of clinically relevant alterations, K-4CARE empowers clinicians to identify the most targetable mutations within each patient's tumor. This information guides the selection of personalized treatment strategies, including targeted therapies and immunotherapies. Additionally, K-4CARE facilitates the monitoring of treatment response, assesses the emergence of drug resistance, and enables vigilant surveillance for early signs of cancer recurrence.
Maximize Treatment Potential
Incorporate K-4CARE Testing for Early-Stage Cancer
Healthy individuals with an
elevated risk of cancers
Early-stage
cancer patients
Radical treatment
Minimal residual disease detection
Metastatic-stage
cancer patients
Therapy selection
Cancer recurrence/ metastasis
Test recommendation
Benefits of Comprehensive genomic profiling
1. Three comprehensive markers for immunotherapy response: PD-L1, TMB, MSI-NGS
473 genes for all solid tumors
2. Somatic mutations for targeted therapy &identification of drug resistance mechanisms
Lastest targeted therapy for all solid tissue tumors
3. Germline mutations are associated with treatment reponse, prognosis & genetic risk assessment for the patient's family
Most common types of heredity cancers
4. Personalized cancer tracking to detect minimal residual disease, monitor treatment response and detect early recurrence
Applied free of charge for cancers fits with MRD
Why K-4CARE
Comprehensive 473-Gene Panel for Solid Tumor Profiling
Comprehensive Biomarker Profiling to Optimize Treatment Selection, Including Targeted Therapy and Immunotherapy.
Empowering Informed Treatment Decision-Making for Doctors and Patients
Comprehensive molecular tumor profiling provides valuable insights. This information facilitates proactive collaboration between clinicians and patients, enabling the selection of the most appropriate treatment strategy.
Save Time + Cost + Precious tissue samples
This comprehensive tumor analysis requires a single test, preserving valuable tissue samples and reducing costs. It provides extensive molecular insights, empowering clinicians to proactively adapt treatment plans based on early indicators of drug resistance, treatment non-response, or disease progression.
Post-Treatment Surveillance and Recurrence Monitoring: Accompanying the Patient
Sample collection
Libraries were prepared using Trusight Oncology 500 kit (Illumina, USA), NEBNext Ultra II FS DNA library preparation kit (New England Biolabs, USA), pooled together and hybridized with probestargeting 473 genes (IDT, USA) for enrichment.
Tissue sample
Block FFPE/FFPE tumor tissue slices
Blood sample
10ml of blood in Streck tube
Process of K-4CARE
6 simples steps to order a K-4CARE test for your patients. The doctor will receive a detailed report containing the Genomic Profiling after 14 days from the time the patients's tissue sample (Use block FFPE/FFPE tumor tissue slices) and blood sample (Use 10ml of blood in a Streck tube) was delivered to Gene Solutions Lab and 30 days for the minimal residual disease (MRD) result).
The doctor orders the profile
The doctor arranges for the patient's tissue and blood sample
Gene solutions arranges shipment & Lab receives the patient's sample
DNA is extracted from the tumor and blood sample
K-4CARE test identifies the unique genomic of a patient's tumor
